Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer

Cancer

Volumn 115, Issue 15, 2009, Pages 3376-3378

  Moul, Judd W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; ANTIANDROGEN; BICALUTAMIDE; DEGARELIX; GONADORELIN; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; ANAPHYLAXIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; FOLLOW UP; HORMONAL THERAPY; HUMAN; JAPANESE; METASTASIS; MONOTHERAPY; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NITRILES; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOSYL COMPOUNDS;

EID: 68149180921     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24393     Document Type: Editorial

References (12)

1. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321:419-424.
2. Akaza H, Hinotsu S, Usami M, et al. Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer. 2009;115:3437-3445.
3. Klotz L, Schellhammer P, Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer [review]. BJU Int. 2004;93:1177-1182.
4. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781-1788.
5. Moul JW, Wu H, Sun L, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004;171:1141-1147.
6. [No authors listed] Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet. 2000;355:1491-1498.
7. Loblaw DA, Virgo KS, Nam R, et al; American Society of Clinical Oncology. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline [review]. J Clin Oncol. 2007;20:25:1596-1605.
8. Ryan CJ, Elkin EP, Small EJ, Duchane J, Carroll P. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urol Oncol. 2006;24:396-402.
9. Isbarn H, Boccon-Gibod L, Carroll PR, et al. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol. 2008 Oct 14. [Epub ahead of print].
10. Debruyne F, Bhat G, Garnick MB. Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer [review]. Future Oncol. 2006;2:677-696.
11. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102:1531-1538.
12. Moul JW, Wiederkehr D, Sendersky V, Connolly M, Stern L, Onel E. The influence of Medicare reform on the utilization of anti-androgens in a cohort of patients with prostate cancer in the United States. J Urol. 2008;179(suppl):30. Abstract 84.